Made in India Sputnik V to be available during Sept-October: Dr Reddy's

RDIF has tied up with six Indian drug makers to manufacture Sputnik V.

Sputnik
Press Trust of India Hyderabad
2 min read Last Updated : Jul 27 2021 | 6:12 PM IST

Dr Reddy's Laboratories Ltd expects the locally manufactured Russia's COVID-19 vaccine Sputnik V to be available from September-October period, a senior official of the city-based drug maker said on Tuesday.

M V Ramana, CEO of Branded Markets (India and Emerging Markets), Dr Reddys, said due to the sudden spike of COVID-19 cases in Russia, the arrival of Sputnik V doses are getting delayed and the situation may ease by August end.

"The local manufacturers are currently in the process of Technology absorption and scale up.

And we expect and from the October-September timeframe we are likely to have locally manufactured sputnik available," Ramana told reporters.

Dr Reddy's, which has tied up with Russian Direct Investment Fund for Sputnik V in India, soft launched the vaccine in India in May 2021 after receiving Emergency Use Authorization (EUA) in April 2021.

Ramana said the company is in discussions with RDIF for ramping up supplies.

RDIF has tied up with six Indian drug makers to manufacture Sputnik V.

Dr Reddy's is in a pact with Russian Direct Investment Fund to sell the first 125 million people doses (250 million vials) of COVID-19 vaccineSputnikVin India.

The official said the vaccine was launched in 80 cities and over 2.5 lakh people have been administered the jab.

Replying to a query, he said the trials of Sputnik V in adolescents have commenced in Russia and they are expected to be completed by October.

On the arrival of more Sputnik V stock from RDIF, Ramana said "What we wait for now is the balance of the second dose and we are in discussions with RDIF.

We do expect to hear back from them by the end of July.

The indications are that in the month of August we should start seeing a bit of floor of the imported product."

Meanwhile, Dr Reddy's, in a press release, said SVAAS Wellness Limited, a wholly-owned subsidiary of the drug maker, tied up with ICICI Lombard General Insurance Company Limited for a pilot launch of a first-of-its-kind cashless outpatient offering in India.

The partnership marks the launch of Dr.Reddys digital health solution 'SVAAS' and demonstrates ICICI Lombards deeper foray into the wellness space.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jul 27 2021 | 6:11 PM IST

Next Story